Tourmaline Bio, Inc. is a biotechnology company focused on the development of innovative therapies harnessing the power of the immune system to treat various diseases, particularly challenging conditions such as cancer and autoimmune disorders
The company leverages advanced technology platforms to engineer and optimize biologic products, aiming to enhance the potential of immune modulation and provide breakthrough treatment options for patients. Through rigorous research and clinical development, Tourmaline Bio is committed to advancing its pipeline of novel therapeutics to transform patient care and improve health outcomes.
Shares of FactSet Research Systems Inc. (NYSEFDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance.
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.52% to 39,718.37 while the NASDAQ rose 0.84% to 16,506.28. The S&P 500 also rose, gaining, 0.53% to 5,252.23.
U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSETDCX) rose sharply during Wednesday’s session after it disclosed receiving a preliminary non-binding acquisition offer.
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQKRTX) rose sharply during Friday’s session following acquisition news.
